Brief: Genfit And Labcorp Sign Exclusive Agreement To Commercialize A Novel Diagnostic Test For Liver Disease

Genfit SA

28/09/2020 07:10

Sept 28 (Reuters) - Genfit SA  GNFT.PA :
    * GENFIT AND LABCORP SIGN EXCLUSIVE AGREEMENT TO
COMMERCIALIZE A
NOVEL DIAGNOSTIC TEST FOR LIVER DISEASE
    * TEST IS EXPECTED TO BE AVAILABLE FROM LABCORP BY EARLY
2021
    * INNOVATIVE MULTI-BIOMARKER BLOOD TEST BASED ON GENFIT'S
NIS4™
TECHNOLOGY IS SPECIFICALLY DESIGNED TO IDENTIFY PATIENTS WITH
AT-RISK NON-ALCOHOLIC STEATOHEPATITIS (NASH)
    * LABCORP TO COMMERCIALIZE TEST FOR CLINICAL CARE USE IN
U.S. AND
CANADA TO HELP IDENTIFY APPROXIMATELY 10 MILLION INDIVIDUALS AT
RISK OF PROGRESSING TO LATE STAGE COMPLICATIONS DUE TO NASH
AMONG TENS OF MILLIONS OF PEOPLE WITH METABOLIC RISK FACTORS AND
SUSPECTED DISEASE

Source text for Eikon:  ID:nGNE5mNgTc 
Further company coverage:  GNFT.PA ;  LH.N 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))